Clinical Trial Update: Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating enzalutamide in combination with the ADC PDS01ADC for PET-positive recurrent prostate cancer in patients not on testosterone-l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• PDS01ADC
• Xtandi (enzalutamide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Prostate Cancer, Recurrent Prostate Cancer | Phase 2 | Status: RECRUITING